Jilin Aodong Pharmaceutical Group Co Ltd (000623) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China.

Total Revenue Chart for Jilin Aodong Pharmaceutical Group Co Ltd

Jilin Aodong Pharmaceutical Group Co Ltd (000623) revenue for FY2025 was CNY 2.3B, a -10.5% change from FY2024. Jilin Aodong Pharmaceutical Group Co Ltd's revenue grew from CNY 173.1M in 1995 to CNY 2.3B in 2025 (1248.8% over 30 years). Earnings per share grew from CNY 0.07 in 2000 to CNY 1.37 in 2022 (1829.3%). Revenue compound annual growth rate: 5-year CAGR of 0.7%, 10-year CAGR of 0.0%, 20-year CAGR of 5.7%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (CNY)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
¥22.27B
Implied Share Price
¥18.62
Enterprise Value
¥21.69B
Revenue (TTM)
¥2.23B
EBITDA
¥38.93M
Profit Margin
123.25%
Trailing P/E
7.96
Forward P/E
14.62
Price/Book (MRQ)
0.71
Price/Sales (TTM)
10.00
EV/EBITDA
7.70
EV/Revenue
9.74
Dividend Yield
2.68%
Book Value
¥26.86
Free Cash Flow (FY2025)
¥143.81M
Free Cash Flow Yield
0.65%

Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.